ARIX.L Share News (ARIX)

Arix Bioscience narrows annual loss but net asset value decreases

(Alliance News) - Arix Bioscience PLC said on Tuesday that losses were reduced in 2022, but net asset value fell.

Arix Bioscience net asset value falls at the end of January

(Alliance News) - Arix Bioscience PLC said on Monday its net asset value at January 31 was 180 pence, down from 182p at the end of October, 2022.

Arix portfolio firm Disc Medicine seals Gemini Therapeutics merger

(Alliance News) - Arix Bioscience PLC on Friday said that its portfolio company has completed a previously announced merger with Gemini Therapeutics Inc, following the approval of Gemini shareholders.

IN BRIEF: Arix Bioscience Chair Moncreiffe buys 78,000 more shares

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Chair Peregrine Moncreiffe buys 78,000 shares at GBP1.04 each, worth GBP81,120 on Wednesday last week. On October 4, Moncreiffe had bought 100,000 shares at 102.94 pence each, worth GBP102,940.

Arix Bioscience says Imara to merge with Enliven Therapeutics

(Alliance News) - Arix Bioscience PLC on Friday said its portfolio company Imara Inc has signed a merger deal with Enliven Therapeutics Inc.

DIRECTOR DEALINGS: M&G chair and new CEO buy GBP450,000 in shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Monday and last week and not separately reported by Alliance News:

IN BRIEF: Arkle Resources restarts drilling at Stonepark project

Arkle Resources PLC - Ireland-based gold and zinc explorer - Says that Group Eleven Resources Corp, its partner and operator for the Stonepark project located near Limerick, Ireland, said that it restarted drilling. Plans to drill the next drill hole on PL3367, roughly 12 kilometres southwest of the Stonepark deposit. Expects all drilling to be completed by year-end.

Arix Bioscience NAV falls; portfolio firm Disc to merge with Gemini

(Alliance News) - Arix Bioscience PLC on Thursday reported a decline in net asset value as public biotech markets did not perform well.

UK earnings, trading statements calendar - next 7 days

UK shareholder meetings calendar - next 7 days

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

EARNINGS UPDATES: Taseko swings to profit; Directa Plus loss narrows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Arix Bioscience says Harpoon ends prostate cancer study

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Notes that portfolio company Harpoon Therapeutics Inc discontinued its phase 1/2 dose-escalation study for HPN424, a treatment for advanced prostate cancer, following a thorough analysis of its HPN424 data. The decision will allow Harpoon to concentrate on HNP328, a treatment in development for tumours associated with delta-like ligand 3 expression, and on HPN 217 for BCMA, an important therapeutic target in the treatment of multiple myeloma.

TRADING UPDATES: Mattioli outlook promising; virus hits Grand Vision

TRADING UPDATES: Mattioli outlook promising; virus hits Grand Vision

IN BRIEF: Arix Bioscience ends buyback; portfolio interest pursues IPO

IN BRIEF: Arix Bioscience ends buyback; portfolio interest pursues IPO